Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Activa

This article was originally published in The Gray Sheet

Executive Summary

Latest iterations of the deep brain stimulation implant for treatment of movement disorders, set for U.S. debut in June, include the Activa RC rechargeable system and Activa PC primary cell non-rechargeable device, both of which incorporate advanced programming and therapy monitoring functions, Medtronic announces May 21. The "next-generation" devices, which provide bi-lateral brain stimulation and treat symptoms of advanced Parkinson's disease and essential tremor, were recently approved via PMA supplement and are the "smallest available," the firm claims. The Activa PC in particular is 20% smaller than previous versions with "similar battery life." The first Activa system was approved in the U.S. in 1997 for treatment of essential and Parkinson's tremor
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT027479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel